Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management.
Case description
A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol.
Conclusions
This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.
Mathers C and Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. GBD 2000 draft methods paper. Geneva, World Health Organization.
2.
Van CutsemECervantesAAdamR, et al.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol2016; 27: 1386–1422.
3.
Cetuximab (package insert). Princeton, NJ: Bristol-Myers; ImClone Inc, February 2004.
4.
JonkerDJO'callaghanCJKarapetisCS, et al.Cetuximab for the treatment of colorectal cancer. N Engl J Med2007; 357: 2040–2048.
5.
Van CutsemEKöhneCHHitreE, et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 360: 1408–1417.
6.
LenzHJVan CutsemEKhambata-FordS, et al.Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol2006; 24: 4914–4921.
7.
O'NeilBHAllenRSpigelDR, et al.High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol2007; 25: 3644–3648.
8.
GeorgeTJJrLaPlantKDWaldenEO, et al.Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol2010; 8: 72–77.
9.
HansenNLChandiramaniDVMorseMA, et al.Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract2011; 17: 125–130.
10.
ChungCHMirakhurBChanE, et al.Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med2008; 358: 1109–1117.
11.
MariotteDDupontBGervaisR, et al.Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. InMAbs2011; 3: 396–401.
12.
MaierSChungCHMorseM, et al.A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med2015; 4: 36–42.
13.
HochsterHSHartLLRamanathanRK, et al.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol2008; 26: 3523–3529.
14.
TournigandCAndréTAchilleE, et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004; 22: 229–237.
15.
SampsonHAMuñoz-FurlongACampbellRL, et al.Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med2006; 47: 373–380.
16.
PowerDGShahMAAsmisTR, et al.Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drug2010; 28: 353–360.
17.
SaifMWPeccerilloJPotterV. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol2009; 63: 1017–1017.
18.
PriceTJPeetersMKimTW, et al.Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol2014; 15: 569–579.
19.
JerathMRKwanMKannarkatM, et al.A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol2009; 123: 260–262.
20.
LenzHJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist2007; 12: 601–609.
21.
Madrigal-BurgaletaRBerges-GimenoMPAngel-PereiraD, et al.Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy2013; 68: 853–861.
22.
SaifMWSyrigosKIHotchkissS, et al.Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol2009; 65: 107–112.
23.
HongDIBankovaLCahillKN, et al.Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol2012; 8: 43–54.
24.
García-MenayaJMCordobés-DuránCGómez-UllaJ, et al.Successful desensitization to cetuximab in a patient with a positive skin test to cetuximab and specific IgE to alpha-gal. J Investig Allergol Clin Immunol2016; 26: 132–134.
25.
CernadasJRBrockowKRomanoA, et al.General considerations on rapid desensitization for drug hypersensitivity – a consensus statement. Allergy2010; 65: 1357–1366.
